PT-141: Mechanism of Action in Research Models

The PT-141 mechanism of action centers on agonist activity across the melanocortin receptor family. Research focuses on the MC3R and MC4R subtypes, which are found in the brain. PT-141, also known as Bremelanotide, is a synthetic ring-shaped peptide of seven amino acids. It is derived from alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied as a stabilized ligand for melanocortin signaling. Read this overview strictly in a research context.

What is the PT-141 mechanism of action in research models?

PT-141 is used as an agonist tool to probe the melanocortin receptor family. An agonist is a molecule that activates a receptor. The findings here come from biochemical assays, cell cultures, and animal models.

Its value comes from its design. Changes to the parent peptide shift activity toward MC3R and MC4R. These subtypes are linked to central nervous system signaling. So labs get a defined probe for those pathways.

The parent peptide, alpha-MSH, acts on all melanocortin receptors without preference. PT-141 is often studied as a comparison tool. It helps separate central receptor activity from the pigment-linked signaling of MC1R. This makes it a useful reference when testing how one ligand engages different receptor subtypes.

PT-141 was built as a stabilized version of alpha-MSH. That stability is part of what makes it a workable probe. The straight-chain parent is quickly cut apart by enzymes in many preparations. The locked ring form lasts long enough to give clean, repeatable signaling data.

So labs use PT-141 not only as a ligand. They also rely on it as a controlled input that behaves the same from assay to assay.

How does melanocortin receptor signaling raise cAMP?

Melanocortin receptors switch on an enzyme that raises cyclic AMP (cAMP) inside the cell. They are G-protein-coupled receptors, classically linked to Gs proteins. When engaged, they activate adenylate cyclase. That enzyme makes cAMP, a common second messenger.

PT-141 is used to study these cAMP-driven cascades. Labs also use it to compare strength across the five subtypes, MC1R through MC5R, in functional assays.

The melanocortin system takes part in central signaling networks. So labs use PT-141 in models of hypothalamic and brain pathways. They map how MC4R activity differs from activity at MC1R and other subtypes.

The usual readout is cAMP build-up. It lets teams compare potency and efficacy against alpha-MSH and other analogs. These same endpoints anchor the study designs in the PT-141 research applications.

What structural features give PT-141 its selectivity?

PT-141 has the structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Three changes set it apart from straight-chain alpha-MSH:

• An acetyl-norleucine at the start of the chain. Norleucine is a non-natural amino acid.
• A lactam bridge that closes a ring between the Asp and Lys residues.
• A D-Phe swap in place of the natural form of phenylalanine.

Together these changes lock the peptide backbone. They also help it resist breakdown by enzymes.

Structure-activity research uses PT-141 to study how these changes affect subtype preference and signal length. The flexible parent peptide is the baseline. The locked ring shape is linked to the focus on MC3R and MC4R. It is also linked to weaker activity at MC1R. That is why the compound serves as a subtype-informative tool, not a broad melanocortin agonist.

The D-Phe swap is a classic way to build resistance to enzymes. Many protein-cutting enzymes do not recognize D-amino acids. The acetyl cap and the lactam ring add to this. The peptide offers fewer sites for enzymes to cut.

In practice, this matters for reading data. Differences in signal length can be credited more confidently to receptor activity. They are less likely to reflect how fast the ligand vanishes from the assay.

How does PT-141 compare with non-selective melanocortin ligands?

PT-141 is often studied next to other melanocortin peptides to put its selectivity in context. The broad agonism in the Melanotan 2 mechanism of action offers a useful contrast. So does the closely related material in the MT-2 mechanism overview.

Against these wide-range ligands, PT-141 is the reference point for probing the central MC3R and MC4R arm.

At the other end of the range sits Melanotan 1. It is more focused on MC1R and pigmentation research. It shows the pigment-linked activity that PT-141 is reported to engage less strongly.

Comparing these three tools lets labs map a gradient within one receptor family. The gradient runs from pigment-linked MC1R signaling to central MC4R signaling.

Which specifications matter for mechanistic work?

Precise identity matters in mechanism studies. PT-141 has these documented specs:

• Molecular formula: C50H68N14O10
• Molecular weight: about 1025.18 g/mol
• CAS number: 189691-06-3
• PubChem CID: 9941379
• Synonyms: Bremelanotide and PT 141

These identifiers let a lab confirm that binding and cAMP data come from the intended peptide, not a related analog. Material with a certificate of analysis is listed on the PT-141 product page. This supports the tracing needed to read subtype selectivity results.

How should PT-141 mechanistic data be read?

Current understanding of PT-141 signaling comes from in vitro assays and animal models. Findings are observations within their test setting. They are not established physiological or clinical outcomes.

Several factors shape the results:

• Subtype potency depends on the receptor system chosen.
• The size of the cAMP signal depends on the assay format.
• Signal length depends on both.

Labs can review prep practice in the PT-141 handling and reconstitution guide before designing binding or functional tests. This keeps material quality aligned with the questions being asked.

For research use only. PT-141 is an investigational research peptide and is not approved for human or veterinary use. All descriptions refer to preclinical and in vitro laboratory research.